On behalf of the GMMMG Medicines Value Group, we now seek comments on an update to the GMMMG Ethical Framework for Considering Rebate Applications from Pharmaceutical, Nutrition and Device Companies in primary care.
Please note this consultation includes two documents, provided in a zipped folder.
Greater Manchester healthcare professionals have collaborated to design the Greater Manchester Pain Management Resources Hub that gathers helpful tools and resources in one place. The Hub brings together a variety of useful resources including guidance to support effective consultations, patient self-management information to share, clinician aids and tools, shared learning and education, how to use data to understand the local population, and information to access related services across the conurbation.
“Pain Killers” do not stop pain, they mask it, and prolonged use can lead to lasting harm including addiction. Healthcare professionals can use the new NHS Greater Manchester Pain Management Resources Hub to support their patients to safely reduce opioids and identify alternatives. Take a look and explore more here: Greater Manchester Pain Management Resources Hub.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their January 2024 meeting. Actions in this consultation include:
FreeStyle Libre 3 – add as RED
Levonorgestrel 20 micrograms / 24 hours intrauterine delivery system (Benilexa) – add as GREEN for contraception and heavy menstrual bleeding, and for endometrial protection as part of HRT (off-label)
Melatonin 1 mg/mL SF oral solution – add Consilient brand as preferred liquid for children aged 5 years and younger, and Ceyesto as preferred liquid for patients aged 6 and older. Use of these products should be limited to when crushing Adaflex tablets is not suitable.
Rimegepant for migraine – amend RAG status to GREEN (specialist advice). Currently on formulary as GREEN (specialist initiation). A separate consultation for a supporting factsheet is also underway; see below.
Secukinumab for hidradenitis suppurativa – RED
Targeted-release budesonide for primary IgA nephropathy – RED
Empagliflozin for CKD – GREEN
Velmanase alfa – RED
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
A supporting document has been produced: Rimegepant (Vydura) factsheet for primary care clinicians, including prescribing criteria, when to refer to neurology, how to review treatment and when to stop treatment.
Thanks go to the GM working group who developed this guidance who are detailed below. Also to GMMMG and the wider GM pharmacy and medicines system for supporting this accelerated development and approval process to enable the rapid dissemination of this information intended to support patients through this medicines shortage. Please cascade this information across your systems.
GM task and finish group:
– Sana Alam – Senior Clinical Pharmacist |Lead CAMHS Pharmacist (GMMH)
– Arifa Azmi – Clinical Pharmacist CAMHS/Antimicrobial and Infection Control (Pennine Care)
– Khadija Mansoorali – Paediatric Mental Health Pharmacist (MFT)
– Nicola Smith – Senior Medicines Optimisation Pharmacist (Trafford)
– Zoe Paine – Senior Medicines Optimisation Pharmacist – Women and Children Lead (Manchester)
– Leigh Lord – Head of Medicines Optimisation and Governance (MFT)
– Jennifer Seal – Senior Medicines Optimisation Pharmacist (Bury)
The decisions made at the Greater Manchester Medicines Management Group (GMMMG) October 2023 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in October 2023 and NICE Technology appraisals published in June 2023.
The following decisions were approved and can be found at: